Dengue Virus and Its Inhibitors: A Brief Review

DOI HANDLE Web Site Web Site PubMed 被引用文献2件 参考文献98件 オープンアクセス
  • Tian Yu-Shi
    Graduate School of Pharmaceutical Sciences, Osaka University
  • Zhou Yi
    Graduate School of Pharmaceutical Sciences, Osaka University
  • Takagi Tatsuya
    Graduate School of Pharmaceutical Sciences, Osaka University
  • Kameoka Masanori
    Department of International Health, Kobe University Graduate School of Health Sciences
  • Kawashita Norihito
    Graduate School of Pharmaceutical Sciences, Osaka University Faculty of Sciences and Engineering, Kindai University

この論文をさがす

抄録

<p>The global occurrence of viral infectious diseases poses a significant threat to human health. Dengue virus (DENV) infection is one of the most noteworthy of these infections. According to a WHO survey, approximately 400 million people are infected annually; symptoms deteriorate in approximately one percent of cases. Numerous foundational and clinical investigations on viral epidemiology, structure and function analysis, infection source and route, therapeutic targets, vaccines, and therapeutic drugs have been conducted by both academic and industrial researchers. At present, CYD-TDV or Dengvaxia® is the only approved vaccine, but potent inhibitors are currently under development. In this review, an overview of the viral life circle and the history of DENVs is presented, and the most recently reported antiviral candidates and newly discovered promising targets are focused and summarized. We believe that these successes and failures have enabled progress in anti-DENV drug discovery and hope that our review will stimulate further innovation in this area.</p>

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (98)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ